Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial.
Strauss GP, Zamani Esfahlani F, Sayama H, Kirkpatrick B, Opler MG, Saoud JB, Davidson M, Luthringer R. Strauss GP, et al. Among authors: luthringer r. Schizophr Bull. 2020 Jul 8;46(4):964-970. doi: 10.1093/schbul/sbz141. Schizophr Bull. 2020. PMID: 31989151 Free PMC article. Clinical Trial.
The brief negative symptom scale (BNSS): Sensitivity to treatment effects.
Kirkpatrick B, Saoud JB, Strauss GP, Ahmed AO, Tatsumi K, Opler M, Luthringer R, Davidson M. Kirkpatrick B, et al. Among authors: luthringer r. Schizophr Res. 2018 Jul;197:269-273. doi: 10.1016/j.schres.2017.11.031. Epub 2017 Dec 21. Schizophr Res. 2018. PMID: 29275856 Clinical Trial.
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial.
Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Rabinowitz J, et al. Among authors: luthringer r. Schizophr Res. 2019 Sep;211:103-104. doi: 10.1016/j.schres.2019.07.029. Epub 2019 Jul 30. Schizophr Res. 2019. PMID: 31375316 Clinical Trial. No abstract available.
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M, Luthringer R. Davidson M, et al. Among authors: luthringer r, luthringer e. Am J Psychiatry. 2017 Dec 1;174(12):1195-1202. doi: 10.1176/appi.ajp.2017.17010122. Epub 2017 Jul 28. Am J Psychiatry. 2017. PMID: 28750582 Clinical Trial.
79 results